Education
About Us
Working with TipRanks
Follow Us
Sunshine Biopharma (SBFM)
NASDAQ:SBFM
SBFM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.90 - $265.25
Previous CloseN/A
Volume70.59K
Average Volume (3M)40.56K
Market Cap
$5.77M
Enterprise Value-$7.61M
Total Cash (Recent Filing)$95.13K
Total Debt (Recent Filing)$1.24M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Apr 08, 2025EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-155.59
Shares Outstanding2,708,341
10 Day Avg. Volume30,863
30 Day Avg. Volume40,558
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.19
Price to Cash Flow (P/CF)-1.10
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.32
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.91
Enterprise Value/Ebitda1.89
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
Sunshine Biopharma News
PremiumCompany Announcements
Sunshine Biopharma Appoints New Chief Commercial Officer
---
Ownership Overview
1.11%
Insiders
<0.01%
Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
SBFM FAQ
What was Sunshine Biopharma’s price range in the past 12 months?
Sunshine Biopharma lowest stock price was $1.90 and its highest was $265.25 in the past 12 months.
What is Sunshine Biopharma’s market cap?
Sunshine Biopharma’s market cap is $5.77M.
When is Sunshine Biopharma’s upcoming earnings report date?
Sunshine Biopharma’s upcoming earnings report date is Apr 08, 2025 which is in 12 days.
How were Sunshine Biopharma’s earnings last quarter?
Sunshine Biopharma released its earnings results on Nov 06, 2024. The company reported -$0.94 earnings per share for the quarter, beating the consensus estimate of -$535 by $534.06.
Is Sunshine Biopharma overvalued?
According to Wall Street analysts Sunshine Biopharma’s price is currently Overvalued.
Does Sunshine Biopharma pay dividends?
Sunshine Biopharma does not currently pay dividends.
What is Sunshine Biopharma’s EPS estimate?
Sunshine Biopharma’s EPS estimate is 0.01.
How many shares outstanding does Sunshine Biopharma have?
Sunshine Biopharma has 2,708,341 shares outstanding.
What happened to Sunshine Biopharma’s price movement after its last earnings report?
Sunshine Biopharma reported an EPS of -$0.94 in its last earnings report, beating expectations of -$535. Following the earnings report the stock price went down -6.294%.
Which hedge fund is a major shareholder of Sunshine Biopharma?
Currently, no hedge funds are holding shares in SBFM
---
Company Description
Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound. It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4. Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
---
SBFM Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Cyclacel Pharmaceuticals
―
Achieve Life Sciences
―
Actinium Pharmaceuticals
―
Avalo Therapeutics
―
Bioxcel Therapeutics
―
---